drugset / Trial / NCT05116787
BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants Not Receiving Other Complement Inhibitor Therapy
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study was to determine the efficacy and safety of BCX9930 monotherapy for the treatment of adult participants with PNH not currently receiving complement inhibitor therapy.
Timeline
- Start
- 2021-10-26
- Primary completion
- 2023-09-18
- Completion
- 2023-09-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BCX9930 | Unknown | 400 mg | Oral |
| Subject | BCX9930 | Unknown | 500 mg | Oral |